300289，重大资产重组！

Core Viewpoint - Lidman plans to acquire up to 70% of Beijing Xiansheng Xiangrui Biological Products Co., Ltd. through cash payment, aiming to gain control over the company and enhance its IVD business segment, particularly in tuberculosis diagnosis and treatment [1][2]. Group 1: Transaction Details - The acquisition involves a cash purchase of shares from shareholders of Xiansheng Xiangrui, with no prior ownership of the target company by Lidman [1]. - The transaction is expected to constitute a major asset restructuring, and Lidman's stock will not be suspended during this process [1][2]. - The funding for the acquisition will come from Lidman's own funds and bank acquisition loans, with the transaction price yet to be determined [2]. Group 2: Company and Industry Insights - Xiansheng Xiangrui operates in the biopharmaceutical manufacturing industry, focusing on in vivo diagnostic reagents and human vaccines, particularly for tuberculosis screening and treatment [1]. - Lidman is one of the earliest companies in China engaged in the research, production, and sales of biochemical diagnostic reagents [2]. - The acquisition is expected to enhance Lidman's competitive edge by adding tuberculosis diagnosis and treatment capabilities, aligning with the interests of the company and its shareholders [2]. Group 3: Market Performance - Lidman's stock has seen a significant increase, with a cumulative rise of over 44% from April 8 to the present, reaching a closing price of 5.87 yuan per share and a total market capitalization of 3.2 billion yuan [3].